TNSN98211A1 - Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant - Google Patents
Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenantInfo
- Publication number
- TNSN98211A1 TNSN98211A1 TNTNSN98211A TNSN98211A TNSN98211A1 TN SN98211 A1 TNSN98211 A1 TN SN98211A1 TN TNSN98211 A TNTNSN98211 A TN TNSN98211A TN SN98211 A TNSN98211 A TN SN98211A TN SN98211 A1 TNSN98211 A1 TN SN98211A1
- Authority
- TN
- Tunisia
- Prior art keywords
- inhibitor
- glycogene
- aldose
- combination
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Noise Elimination (AREA)
- Superheterodyne Receivers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'INVENTION CONCERNE DES ASSOCIATIONS D'INHIBITEURS D'ALDOSE - REDUCTASE ET D'INHIBITEURS DE GLYCOGENE-PHOSPHORYLASE. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES ASSOCIATIONS. APPLICATION : UTILISATION DE CES COMPOSITIONS POUR LE TRAITEMENT D'ETATS DE RESISTANCE A L'INSULINE TELS QUE LE DIABETE ET POUR LA REDUCTION D'UNE ALTERATION TISSULAIRE DUE A UNE ISCHEMIE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6636597P | 1997-11-21 | 1997-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN98211A1 true TNSN98211A1 (fr) | 2005-03-15 |
Family
ID=22069038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN98211A TNSN98211A1 (fr) | 1997-11-21 | 1998-11-18 | Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1032424B9 (fr) |
JP (1) | JP2002504478A (fr) |
KR (2) | KR20010032304A (fr) |
CN (1) | CN1279617A (fr) |
AP (1) | AP911A (fr) |
AR (1) | AR016423A1 (fr) |
AT (1) | ATE205403T1 (fr) |
AU (1) | AU733304B2 (fr) |
BG (1) | BG104435A (fr) |
BR (1) | BR9814698A (fr) |
CA (1) | CA2310069A1 (fr) |
DE (1) | DE69801680T2 (fr) |
DK (1) | DK1032424T3 (fr) |
DZ (1) | DZ2656A1 (fr) |
EA (1) | EA002365B1 (fr) |
ES (1) | ES2161548T3 (fr) |
GR (1) | GR3037071T3 (fr) |
GT (1) | GT199800166A (fr) |
HR (1) | HRP20000327A2 (fr) |
HU (1) | HUP0100272A3 (fr) |
ID (1) | ID24524A (fr) |
IL (1) | IL135713A0 (fr) |
IS (1) | IS5453A (fr) |
MA (1) | MA26568A1 (fr) |
NO (1) | NO20002164L (fr) |
OA (1) | OA11379A (fr) |
PA (1) | PA8462301A1 (fr) |
PE (1) | PE135399A1 (fr) |
PL (1) | PL340643A1 (fr) |
PT (1) | PT1032424E (fr) |
SK (1) | SK7222000A3 (fr) |
TN (1) | TNSN98211A1 (fr) |
TR (1) | TR200001451T2 (fr) |
UA (1) | UA57811C2 (fr) |
UY (1) | UY25258A1 (fr) |
WO (1) | WO1999026659A1 (fr) |
YU (1) | YU30700A (fr) |
ZA (1) | ZA9810636B (fr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047206A1 (fr) * | 1999-02-12 | 2000-08-17 | Novo Nordisk A/S | Utilisation de derives de pyrrolidine pour la preparation d'une composition pharmaceutique destinee au traitement ou a la prevention de l'obesite ou a la regulation de l'appetit |
JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物 |
CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
WO2002098429A1 (fr) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
CA2392486A1 (fr) | 2002-07-05 | 2002-12-08 | Duchesnay Inc. | Forme posologique pharmaceutique portant une inscription pour les femmes enceintes |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
ES2524916T3 (es) | 2003-11-12 | 2014-12-15 | Sino-Med International Alliance, Inc. | Compuestos heterocíclicos de ácido borónico |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
WO2006017292A1 (fr) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Composes cyano contraints |
US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US20070060528A1 (en) | 2005-09-14 | 2007-03-15 | Christopher Ronald J | Administration of dipeptidyl peptidase inhibitors |
EP2046753A2 (fr) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2008130951A1 (fr) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase hétérocyclique condensés de type i |
ES2388967T3 (es) | 2007-05-04 | 2012-10-22 | Bristol-Myers Squibb Company | Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G |
JP2010526146A (ja) | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | [6,5]−二環式gpr119gタンパク質結合受容体アゴニスト |
PE20090888A1 (es) | 2007-07-17 | 2009-07-15 | Bristol Myers Squibb Co | Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119 |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
WO2011041293A1 (fr) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose |
PT2531501E (pt) | 2010-02-03 | 2014-02-17 | Takeda Pharmaceutical | Inibidores da cinase de regulação do sinal de apoptose 1 |
EA201270755A1 (ru) | 2010-04-08 | 2013-03-29 | Бристол-Майерс Сквибб Компани | Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119 |
WO2011130459A1 (fr) | 2010-04-14 | 2011-10-20 | Bristol-Myers Squibb Company | Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs |
EA201270778A1 (ru) | 2010-05-06 | 2013-04-30 | Бристол-Майерс Сквибб Компани | Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119 |
EP2566862B1 (fr) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Analogues de benzofuranyle en tant que modulateurs de gpr119 |
HUE026715T2 (en) | 2011-01-20 | 2016-07-28 | Bionevia Pharmaceuticals Inc | Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use |
EP2850073B1 (fr) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Analogues de pyrimidinylpipéridinyloxypyridone en tant que modulateurs de gpr119 |
WO2015061272A1 (fr) | 2013-10-22 | 2015-04-30 | Bristol-Myers Squibb Company | Inhibiteurs de triazolopyridine 11-bêta hydroxystéroïde déshydrogénase de type 1 à marquage isotopique |
US10604541B2 (en) | 2016-07-22 | 2020-03-31 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4825448A (en) * | 1986-08-07 | 1989-04-25 | International Mobile Machines Corporation | Subscriber unit for wireless digital telephone system |
EP0343273B1 (fr) * | 1988-05-27 | 1994-04-27 | Deutsche ITT Industries GmbH | Circuit de correction pour une paire de signaux numériques en quadrature |
US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
JP3068200B2 (ja) * | 1995-06-06 | 2000-07-24 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ阻害剤としての置換n−(インドール−2−カルボニル−)アミドおよび誘導体 |
CA2224062C (fr) * | 1995-06-06 | 2001-09-04 | Pfizer Limited | (indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase |
-
1998
- 1998-02-11 UA UA2000052869A patent/UA57811C2/uk unknown
- 1998-10-27 GT GT199800166A patent/GT199800166A/es unknown
- 1998-10-28 PA PA19988462301A patent/PA8462301A1/es unknown
- 1998-11-02 PL PL98340643A patent/PL340643A1/xx unknown
- 1998-11-02 EP EP98949193A patent/EP1032424B9/fr not_active Expired - Lifetime
- 1998-11-02 DK DK98949193T patent/DK1032424T3/da active
- 1998-11-02 SK SK722-2000A patent/SK7222000A3/sk unknown
- 1998-11-02 PT PT81300054T patent/PT1032424E/pt unknown
- 1998-11-02 ES ES98949193T patent/ES2161548T3/es not_active Expired - Lifetime
- 1998-11-02 BR BR9814698-0A patent/BR9814698A/pt not_active IP Right Cessation
- 1998-11-02 JP JP2000521860A patent/JP2002504478A/ja active Pending
- 1998-11-02 ID IDW20000958A patent/ID24524A/id unknown
- 1998-11-02 EA EA200000433A patent/EA002365B1/ru not_active IP Right Cessation
- 1998-11-02 WO PCT/IB1998/001752 patent/WO1999026659A1/fr not_active Application Discontinuation
- 1998-11-02 IL IL13571398A patent/IL135713A0/xx unknown
- 1998-11-02 AT AT98949193T patent/ATE205403T1/de not_active IP Right Cessation
- 1998-11-02 YU YU30700A patent/YU30700A/sh unknown
- 1998-11-02 CA CA002310069A patent/CA2310069A1/fr not_active Abandoned
- 1998-11-02 KR KR1020007005514A patent/KR20010032304A/ko not_active Application Discontinuation
- 1998-11-02 CN CN98811329A patent/CN1279617A/zh active Pending
- 1998-11-02 TR TR2000/01451T patent/TR200001451T2/xx unknown
- 1998-11-02 AU AU95558/98A patent/AU733304B2/en not_active Ceased
- 1998-11-02 HU HU0100272A patent/HUP0100272A3/hu unknown
- 1998-11-02 DE DE69801680T patent/DE69801680T2/de not_active Expired - Fee Related
- 1998-11-16 PE PE1998001113A patent/PE135399A1/es not_active Application Discontinuation
- 1998-11-18 DZ DZ980266A patent/DZ2656A1/fr active
- 1998-11-18 TN TNTNSN98211A patent/TNSN98211A1/fr unknown
- 1998-11-19 MA MA25356A patent/MA26568A1/fr unknown
- 1998-11-19 AP APAP/P/1998/001401A patent/AP911A/en active
- 1998-11-19 AR ARP980105883A patent/AR016423A1/es not_active Application Discontinuation
- 1998-11-19 UY UY25258A patent/UY25258A1/es not_active Application Discontinuation
- 1998-11-20 ZA ZA9810636A patent/ZA9810636B/xx unknown
-
1999
- 1999-05-07 KR KR1020007013394A patent/KR100661214B1/ko not_active IP Right Cessation
-
2000
- 2000-04-14 IS IS5453A patent/IS5453A/is unknown
- 2000-04-27 NO NO20002164A patent/NO20002164L/no not_active Application Discontinuation
- 2000-05-12 OA OA1200000137A patent/OA11379A/en unknown
- 2000-05-15 BG BG104435A patent/BG104435A/bg unknown
- 2000-05-19 HR HR20000327A patent/HRP20000327A2/hr not_active Application Discontinuation
-
2001
- 2001-10-30 GR GR20010401943T patent/GR3037071T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN98211A1 (fr) | Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN96085A1 (fr) | Amides therapeutiques et compositions les contenant | |
TNSN99053A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant | |
TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN96104A1 (fr) | Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant | |
MA24729A1 (fr) | Macrolides nouveaux. | |
TNSN01125A1 (fr) | Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine | |
BR9806060A (pt) | Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina. | |
TNSN01170A1 (fr) | Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase. | |
TNSN98084A1 (fr) | Derives de macrolides substitues en position c-4 | |
TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
BR9909358A (pt) | Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito | |
NL300175I1 (nl) | Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2. | |
MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
TNSN99252A1 (fr) | Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant. | |
TNSN01119A1 (fr) | Compositions contenant des inhibiteurs de la proteine de transfert d'ester de cholesteryle | |
BR9814327A (pt) | Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose | |
PE44895A1 (es) | Compuesto derivado de benzotiofeno que puede inhibir la perdida osea y disminuir el colesterol en suero | |
TNSN97139A1 (fr) | Derives d'acides d'arylsulfonylaminohydroxamiques | |
ES2131185T3 (es) | Arilalcanil-n-hidroxiureas y heteroalquilalcanil-n-hidroxiureas sustituidas que pueden inhibir la biosintesis de leucotrienos. | |
ATE234282T1 (de) | Polymorphe verbindungen | |
MY138289A (en) | Pharmaceutical compositions | |
EE04356B1 (et) | aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis |